drugset / Trial / NCT03966079

Thrombolysis Endovascular Treatment of Pulmonary Embolism

NCT03966079

Phase 3 Completed 50 enrolled Beijing Tsinghua Chang Gung Hospital
NaSingle-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of endovascular thrombolysis of pulmonary embolism with right ventricular dysfunction with single-dose rtPA

Timeline

Start
2017-01-01
Primary completion
2020-01-31
Completion
2020-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 20 mg Other

Indications